SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-25-000578 to Shuttle Pharmaceuticals Holdings, Inc. (SHPH)

Shuttle Pharmaceuticals Holdings, Inc.
Date: Jan. 21, 2025 · CIK: 0001757499 · Accession: 0000000000-25-000578

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-284286

Date
January 21, 2025
Author
Anatoly Dritschilo
Form
UPLOAD
Company
Shuttle Pharmaceuticals Holdings, Inc.

Letter

January 21, 2025 Anatoly Dritschilo Chief Executive Officer Shuttle Pharmaceuticals Holdings, Inc. 401 Professional Drive, Suite 260 Gaithersburg, MD 20879 Re:Shuttle Pharmaceuticals Holdings, Inc. Registration Statement on Form S-1 Filed January 15, 2025 File No. 333-284286 Dear Anatoly Dritschilo: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Megan J. Penick, Esq.

Show Raw Text
January 21, 2025
Anatoly Dritschilo
Chief Executive Officer
Shuttle Pharmaceuticals Holdings, Inc.
401 Professional Drive, Suite 260
Gaithersburg, MD 20879
Re:Shuttle Pharmaceuticals Holdings, Inc.
Registration Statement on Form S-1
Filed January 15, 2025
File No. 333-284286
Dear Anatoly Dritschilo:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Megan J. Penick, Esq.